Clinical trials: Alzheimer's Disease(AD)
Dementia, Early Onset, Alzheimer Dementia (AD)
Genetic Studies of Early-onset Dementia
The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease…
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Trial name
- NCT04906863
- Testing
- Blood draw, Neurocognitive testing, Medical questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer's Disease
Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome…
- Trial name
- SARTAN-AD (NCT02085265)
- Testing
- Perindopril, Telmisartan
- Where
- 10 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimer's Disease, Dementias
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
To establish a cutoff value using a ratio of CSF tau to Aβ42 (tau/Aβ42) for distinguishing patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects.
- Trial name
- NCT01730430
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Alzheimer's Disease, Dementia
A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia
The purpose of the study is to evaluate the safety and tolerability of acupuncture for patients with BPSD \& healthy volunteers.
- Trial name
- NCT01055561
- Testing
- Acupuncture
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Mild Cognitive Impairment, Alzheimer's Disease
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
The purpose of this research study is to investigate the effect of a light treatment on sleep, memory and brain function. In people with mild cognitive impairment (MCI) and Alzheimer's disease, sleep-wake disturbance is evident…
- Trial name
- NCT05596994
- Testing
- Lighting Intervention Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Mild Cognitive Impairment (MCI), Dementia
An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers.
- Trial name
- NCT07127133
- Testing
- Insole and ankle device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Alzheimer's Disease (AD)
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
- Trial name
- MOIPAD (NCT06924359)
- Testing
- Multimodal Ophthalmic Imaging and plasma biomarker
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Alzheimer Disease(AD), Sarcopenia
Silkworm Pupa Powder Improves Dementia.
The purpose of this clinical trial is to determine whether silkworm pupa powder is effective in treating Alzheimer's disease. It will also investigate whether silkworm pupa powder can improve the nutritional and frailty status of…
- Conditions
- Alzheimer Disease(AD), Sarcopenia, Asthenia
- Trial name
- NCT06898476
- Testing
- Silkworm pupa powder
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Provincial Tongde Hospital
Alzheimer Disease (AD), Cognitive Dysfunction, Cognitive Disorder
Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease
This prospective study recruited 20 healthy volunteers and 50 patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) according to clinical guidelines.
- Conditions
- Alzheimer Disease (AD), Cognitive Dysfunction, Cognitive Disorder, PET Imaging
- Trial name
- NCT07114224
- Testing
- AV45/AV-1、AV1451 PET
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Mild to Moderate Alzheimer's Disease
Study of LM11A-31-BHS in Mild-moderate AD Patients
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
- Trial name
- NCT03069014
- Testing
- 400mg LM11A-31-BHS, 800mg LM11A-31-BHS
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 242 people
- Sponsor
- PharmatrophiX Inc.
Cognitive Dysfunction
Integrative Therapy for Holistic, Natural Cognition and Lifestyle Rehabilitation
An observational study to determine outcomes of older adults who are under naturopathic medical care for cognitive complaints at a specific clinic in Southern California.
- Trial name
- ITHNCLR (NCT04284449)
- Testing
- Whole-practice cognitive optimization
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National University of Natural Medicine
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)).
- Trial name
- AD-MINER (NCT07089303)
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Alzheimer's Disease
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
Over 5 million Americans have Alzheimer's disease or a related dementia, a progressive and irreversible neurodegenerative condition, affecting also close to 15 million family caregivers (CG).
- Trial name
- NCT01920672
- Testing
- Timed Planned Activity, Home Safety and Education Program
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Alzheimer's Disease
Online Caregiver Psychoeducation and Support for Alzheimer's
This study is piloting an internet-based intervention to provide support for caregivers of VA patients with Alzheimer's disease or related memory difficulties (ADRD).
- Trial name
- NCT00416078
- Testing
- caregiver website support, caregiver brief supportive phone calls
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- US Department of Veterans Affairs
Alzheimer's Disease, Dementia
Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention
A 20+ year randomized controlled trial (RCT) demonstrated the many benefits of a counseling and support intervention for spouse caregivers, the NYU Caregiver Intervention (NYUCI).
- Trial name
- NCT02347202
- Testing
- Online counseling via Zoom teleconferencing, Telephone support as needed
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00093951
- Testing
- SGS742
- Where
- 59 sites in United States
- Volunteers
- 280 people
- Sponsor
- Saegis Pharmaceuticals